TY - JOUR T1 - Addition of omeprazole to dual antiplatelet therapy with clopidogrel plus aspirin lowers the risk of upper gastrointestinal bleeding JF - Evidence Based Medicine JO - Evid Based Med SP - 144 LP - 145 DO - 10.1136/ebm1304 VL - 16 IS - 5 AU - Jolanta M Siller-Matula AU - Georg Delle-Karth Y1 - 2011/10/01 UR - http://ebm.bmj.com/content/16/5/144.abstract N2 - Commentary on: Bhatt DL, Cryer BL, Contant CF, et al.; COGENT Investigators. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010;363:1909–17.OpenUrlCrossRefPubMedWeb of Science Antiplatelet therapy represents the mainstay of treatment for patients undergoing percutaneous coronary intervention.1 However, an increased risk for gastrointestinal bleeding is associated with use of aspirin and clopidogrel. To reduce the bleeding risk, proton pump inhibitors (PPIs) are prescribed in combination with platelet inhibitors, a strategy that is recommended by existing consensus guidelines2 though no randomised trial has proved this. Recently, a pharmacodynamic drug–drug interaction has been shown for clopidogrel and omeprazole but not for pantoprazole.3 4 Whether this interaction has an impact on patient outcomes has not been investigated in a randomised trial. Clopidogrel and the Optimization of Gastrointestinal Events (COGENT) was a randomised, double-blind, placebo-controlled, phase III trial of the efficacy and safety of CGT-2168 (clopidogrel 75 mg and omeprazole 20 mg) compared with clopidogrel 75 mg alone. Patients were included in the trial if they were ≥21 years of age and treatment … ER -